AHFS Drug Information on Windows Pc

"Try before you buy" - Download the FREE App, which includes sample content. In-App purchase required to unlock all content.

AHFS® Drug Information™ - Doody's Core Title - is your comprehensive, interactive treatment and drug therapy solution - complete with therapeutic guidelines and off-label uses.

2020, 2021, 2022, 2023, 2024 Doody's Core Titles List Selection

AHFS Drug Information® 2025 contains the most dependable drug information available—all in one place. It is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses.

With expanded and revised content supported by more than 97,000 references and incorporating the advice of numerous subject matter experts, AHFS DI helps you protect your patients and your practice.

Updates in the new edition:

- Clinical perspective sections that include place of therapy discussions and recommendations from therapeutic guidelines
- Expanded coverage of specialty medications used to treat a variety of complex, chronic conditions that often require special handling and administration and may require careful oversight to manage severe adverse effects and dosage adjustments
- Contemporary topics such as vaccines and treatments for mPox disease, new RSV treatments and vaccines, safety issues associated with the glucagon-like peptide 1 (GLP-1) agonists, novel orphan drugs, biosimilars, and more
- Expanded content on new and emerging gene therapies
- Pharmacogenomic considerations in drug dosing and selection
- Updates to a variety of vaccine monographs including the influenza, COVID-19, pneumococcal, and RSV vaccines with the latest recommendations from the CDC Advisory Committee on Immunization Practices (ACIP)
- Expanded content on off-label uses, real world data and long-term clinical data
- MedWatch alerts, Standardize4Safety concentration standards for IV and oral liquid medications, REMS data, and focused updates based on FDA safety findings
- New content on over 200 new molecular entities (NMEs) or new therapeutic biological products and substantive revisions on approximately 265 medications
- Oncology off-label determinations based on reviews by the AHFS Oncology Expert Committee

Content licensed from printed ISBN 10: 158528761X
Content licensed from printed ISBN 13: 9781585287611

SUBSCRIPTION :

Please purchase a yearly auto-renewing subscription to receive content access and available updates.

Yearly auto-renewing payments- $99.99

Payment will be charged to your mode of payment you select at confirmation of purchase. Subscription automatically renews unless auto-renew is turned off at least 24-hours before the end of the current period. Subscription may be managed by the user and auto-renewal can be disabled at any time by going to your App “Settings” and tapping “Manage Subscriptions”. Any unused portion of a free trial period will be forfeited when you purchase a subscription, where applicable.

Privacy Policy - https://www.skyscape.com/terms-of-service/privacypolicy.aspx
Terms and Conditions - https://www.skyscape.com/terms-of-service/licenseagreement.aspx

Editor(s): American Society of Health-System Pharmacists, Inc.
Publisher: American Society of Health-System Pharmacists, Inc.

- Added New monographs (10): Crinecerfont, Landiolol Hydrochloride, Olezarsen Sodium, Remestemcel-L-rknd, etc.
- Revised monographs (38): Darbepoetin Alfa, Eculizumab, Guselkumab, Guselkumab, etc.

Allows applications to open network sockets.
Allows applications to access information about networks.
Allows using PowerManager WakeLocks to keep processor from sleeping or screen from dimming.
Allows an application to record audio.
Allows applications to disable the keyguard if it is not secure.
Allows an application to write to external storage.
Allows an application to read from external storage.